Drugs / HH-120 Nasal Spray
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT05787418 | Mar 2023 → Dec 2025 overdue | COVID-19 | Huahui Health | Enrolling by invitation | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05747677 | Jun 2022 → Feb 2023 | COVID-19 | Beijing Ditan Hospital | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HH-120 Nasal Spray | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05747677 ↗ |
| Route | Intranasal | “HH-120 nasal spray, 1 spray to each nostril of the participant each time,8-10 times per day” NCT05747677 ↗ |